NL300840I2 - - Google Patents

Download PDF

Info

Publication number
NL300840I2
NL300840I2 NL300840C NL300840C NL300840I2 NL 300840 I2 NL300840 I2 NL 300840I2 NL 300840 C NL300840 C NL 300840C NL 300840 C NL300840 C NL 300840C NL 300840 I2 NL300840 I2 NL 300840I2
Authority
NL
Netherlands
Application number
NL300840C
Other languages
Dutch (nl)
Original Assignee
Abbvie Biotherapeutics Inc
Dana-Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300840(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc, Dana-Farber Cancer Institute Inc filed Critical Abbvie Biotherapeutics Inc
Publication of NL300840I2 publication Critical patent/NL300840I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NL300840C 2006-08-07 2016-10-25 NL300840I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
NL300840I2 true NL300840I2 (enExample) 2017-01-03

Family

ID=38831279

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300840C NL300840I2 (enExample) 2006-08-07 2016-10-25

Country Status (23)

Country Link
US (4) US8632772B2 (enExample)
EP (5) EP2942057A1 (enExample)
JP (1) JP5340935B2 (enExample)
CN (1) CN101686971B (enExample)
AU (1) AU2007281684C1 (enExample)
BR (1) BRPI0716647A2 (enExample)
CA (1) CA2660356C (enExample)
CY (5) CY1116247T1 (enExample)
DK (2) DK2641601T3 (enExample)
ES (2) ES2589302T3 (enExample)
HR (2) HRP20150449T1 (enExample)
HU (4) HUE029027T2 (enExample)
IL (2) IL196919A (enExample)
LT (4) LT2641601T (enExample)
LU (3) LU93276I2 (enExample)
MX (1) MX2009001441A (enExample)
NL (1) NL300840I2 (enExample)
NO (1) NO346835B1 (enExample)
NZ (1) NZ574978A (enExample)
PL (2) PL2641601T3 (enExample)
PT (2) PT2641601T (enExample)
SI (2) SI2641601T1 (enExample)
WO (1) WO2008019378A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2641601T (pt) 2006-08-07 2016-10-14 Dana Farber Cancer Inst Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
PL2068930T3 (pl) * 2006-08-07 2013-02-28 Abbvie Biotherapeutics Inc Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego
JP2011523560A (ja) * 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
JP2011524421A (ja) * 2008-06-16 2011-09-01 イミュノジェン・インコーポレーテッド 新規の相乗効果
BRPI0919668A2 (pt) * 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
ES2502541T3 (es) * 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
US8841325B2 (en) * 2009-11-24 2014-09-23 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CA2888803A1 (en) 2012-11-05 2014-05-08 Jooeun Bae Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US10034872B2 (en) * 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
US20170355768A1 (en) * 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
JP7160533B2 (ja) * 2015-05-13 2022-10-25 モルフォシス・アーゲー 多発性骨髄腫（ｍｍ）の処置
SI3313528T1 (sl) * 2015-06-29 2021-11-30 Bristol-Myers Squibb Company Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
AU2018372924A1 (en) * 2017-11-22 2020-04-23 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
CN115368462B (zh) * 2022-07-19 2026-01-02 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
JPH11511746A (ja) 1995-05-25 1999-10-12 バクスター、インターナショナル、インコーポレイテッド 同種幹細胞移植後の癌の同種細胞治療
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2272513A1 (en) * 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) * 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
WO2008019379A2 (en) 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
PT2641601T (pt) 2006-08-07 2016-10-14 Dana Farber Cancer Inst Inc Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib
PL2068930T3 (pl) 2006-08-07 2013-02-28 Abbvie Biotherapeutics Inc Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego

Also Published As

Publication number Publication date
EP2942057A1 (en) 2015-11-11
US20170342150A1 (en) 2017-11-30
AU2007281684B2 (en) 2013-05-16
LTC2068874I2 (lt) 2018-11-12
US20080152646A1 (en) 2008-06-26
LU93276I2 (fr) 2016-12-27
US20160137735A1 (en) 2016-05-19
LTPA2016031I1 (lt) 2016-11-10
IL196919A (en) 2016-03-31
HUS1600044I1 (hu) 2016-12-28
ES2535437T3 (es) 2015-05-11
CY1117992T1 (el) 2017-05-17
WO2008019378A1 (en) 2008-02-14
NO20090968L (no) 2009-04-30
EP2641600A1 (en) 2013-09-25
HK1129853A1 (en) 2009-12-11
PT2641601T (pt) 2016-10-14
SI2641601T1 (sl) 2016-11-30
EP2641601B1 (en) 2016-07-06
EP2068874B1 (en) 2015-01-28
BRPI0716647A2 (pt) 2017-05-16
CY1116247T1 (el) 2017-02-08
IL243933A0 (en) 2016-04-21
PL2641601T3 (pl) 2017-01-31
US20140322201A1 (en) 2014-10-30
IL196919A0 (en) 2009-11-18
LU93275I2 (fr) 2016-12-27
CY2016036I2 (el) 2017-07-12
CY2016037I1 (el) 2017-07-12
NZ574978A (en) 2012-08-31
CN101686971A (zh) 2010-03-31
DK2641601T3 (en) 2016-08-22
SI2068874T1 (sl) 2015-06-30
LTPA2016030I1 (lt) 2016-11-10
AU2007281684A1 (en) 2008-02-14
HRP20161284T1 (hr) 2016-12-16
CY2016036I1 (el) 2017-07-12
CA2660356C (en) 2016-04-05
NO346835B1 (no) 2023-01-23
HUS1600043I1 (hu) 2016-12-28
JP5340935B2 (ja) 2013-11-13
CY2016038I1 (el) 2017-07-12
DK2068874T3 (da) 2015-04-27
EP2068874A1 (en) 2009-06-17
CN101686971B (zh) 2013-09-11
LU93277I2 (fr) 2016-12-27
LT2641601T (lt) 2016-10-10
HRP20150449T1 (xx) 2015-06-05
MX2009001441A (es) 2009-07-06
JP2010500371A (ja) 2010-01-07
HUE029027T2 (en) 2017-01-30
PL2068874T3 (pl) 2015-06-30
US8632772B2 (en) 2014-01-21
EP2641601A1 (en) 2013-09-25
HUS1600045I1 (hu) 2016-12-28
LTPA2016029I1 (lt) 2016-11-10
EP2641601B8 (en) 2016-09-21
PT2068874E (pt) 2015-05-21
ES2589302T3 (es) 2016-11-11
EP3115049A1 (en) 2017-01-11
AU2007281684C1 (en) 2013-12-19
CA2660356A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
CN300729951S (zh) 断路器(南京m3)
CN300727930S (zh) 挂毯(28)
CN300726893S (zh) 包装盒(冬虫夏草)
CN300727223S (zh) 空中交通管制中心系统席位机架(封闭式)
CN300728223S (zh) 暖风机(hph卧式)
CN300728694S (zh) 毛料布(春晓格)
CN300728732S (zh) 激光全息镭射防伪膜（纸、烫印箔）
CN300725936S (zh) 童装(3850)
CN300725929S (zh) 童装(3811)
CN300728471S (zh) 干发机(hd656)
CN300728128S (zh) 鱼线钳
CN300730099S (zh) 门厅电话
CN300726109S (zh) 牙刷板(p-417)
CN300727494S (zh) 接线端子(uj2-4/2×2)
CN300728979S (zh) 办公椅座靠垫(车缝5501)
CN300730405S (zh) 玩具(海盗船b)
CN300726499S (zh) 家具用线条(1)
CN300727060S (zh) 铅笔包装袋(176)
CN300731826S (zh) 电木铣工作台
CN300729537S (zh) 包装袋(天然芋饺)
CN300729414S (zh) 包装盒(凤凰卷)
CN300729559S (zh) 包装袋(金树味精)
CN300726229S (zh) 玻璃(g06-110bt)
CN300731114S (zh) 拖鞋(3173)
CN300728832S (zh) 理发椅(1806)